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Abstract
Background: We conducted a randomized controlled trial of a digital health system supporting clinical care through monitoring
and self-management support in community-based patients with moderate to very severe chronic obstructive pulmonary disease
(COPD).
Objective: The aim of this study was to determine the efficacy of a fully automated Internet-linked, tablet computer-based
system of monitoring and self-management support (EDGE‚ sElf-management anD support proGrammE) in improving quality
of life and clinical outcomes.
Methods: We compared daily use of EDGE with usual care for 12 months. The primary outcome was COPD-specific health
status measured with the St George’s Respiratory Questionnaire for COPD (SGRQ-C).
Results: A total of 166 patients were randomized (110 EDGE, 56 usual care). All patients were included in an intention to treat
analysis. The estimated difference in SGRQ-C at 12 months (EDGE−usual care) was −1.7 with a 95% CI of −6.6 to 3.2 (P=.49).
The relative risk of hospital admission for EDGE was 0.83 (0.56-1.24, P=.37) compared with usual care. Generic health status
(EQ-5D, EuroQol 5-Dimension Questionnaire) between the groups differed significantly with better health status for the EDGE
group (0.076, 95% CI 0.008-0.14, P=.03). The median number of visits to general practitioners for EDGE versus usual care were
4 versus 5.5 (P=.06) and to practice nurses were 1.5 versus 2.5 (P=.03), respectively.
Conclusions: The EDGE clinical trial does not provide evidence for an effect on COPD-specific health status in comparison
with usual care, despite uptake of the intervention. However, there appears to be an overall benefit in generic health status; and the
effect sizes for improved depression score, reductions in hospital admissions, and general practice visits warrants further
evaluation and could make an important contribution to supporting people with COPD.
Trial registration: International Standard Randomized Controlled Trial Number (ISRCTN): 40367841;
http://www.isrctn.com/ISRCTN40367841 (Archived by WebCite at http://www.webcitation.org/6pmfIJ9KK)
(J Med Internet Res 2017;19(5):e144)   doi:10.2196/jmir.7116
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Introduction
Background
Chronic obstructive pulmonary disease (COPD) is a major cause
of morbidity and mortality [1], with global costs of US $141
billion. In the United Kingdom, the total annual estimated cost
of COPD to the National Health Service (NHS) is over £800
million, over half attributable to hospital-based care [2]. The
impact of COPD on the health-related quality of life of patients
is well-established [3,4].
Correct use of long-acting beta-agonists alone or in combination
with anti-inflammatory inhaled steroids can reduce the overall
rate of exacerbations by 20% [5]. Early recognition of and
intervention during an exacerbation can also reduce admission
risk [6]. Training and support for patients in the
self-management of their condition, for example, through
outpatient pulmonary rehabilitation [7], improves quality of life
and can reduce unplanned hospital admissions [8-10]. There is
an evidence base for use of psychological therapies such as
cognitive behavioral therapy [11], although a wider range of
interventions designed to promote self-management do not
appear to work consistently, possibly because of nonadherence
to the self-management program or to action plans put in place
[12,13], or because not all the components required to improve
self-management are included.
There is a need to identify different forms of self-management
that can improve outcomes and to develop and optimize ways
of delivering available interventions to maximize effectiveness
and safety. Delivery of interventions at a widescale and
continuing the intervention over time are likely to be important
factors addressing feasibility and maintaining effectiveness.
Use of converging computer and communication technologies
in the form of digital health interventions offers a means of
helping patients monitor their condition, providing support in
interpreting data for self-management, and supplying a means
of delivering individually tailored education and treatment plans.
Digital Health Intervention
Digital health interventions in COPD are increasingly employed,
and particularly health apps have been found to show potential
in improving symptoms management through self-management
support [14]. Current digital health interventions and apps
include a range of components, and mainly differ in the
combination of tools used (patient education materials, exercise
support, self-care plans, remote monitoring of symptoms, and
clinical parameters) and input from clinicians (interpretation of
patient data and feedback to patient through phone calls, text
chats, or video calls) [15,16].
Understanding the heterogeneous nature of COPD events with
a variable time course of symptom onset and recovery is
particularly important to underpin interventions that may work
for individual patients [17].
Systematic reviews of digital health interventions till date in
COPD provide evidence to support continuing research [18],
but recent large-scale evaluations have not shown convincing
evidence of their effectiveness [19,20]. Three large trials of
telehealth solutions for COPD have identified little or no benefit
[19,21,22]. Limitations of current systems have included low
compliance rates with the technology resulting from having to
engage with a dedicated telehealth box; lack of flexibility in the
technical specification; artifacts in data collection leading to
high rates of false alerts; and limited personalization and support
for self-management in the telehealth solution. Therefore,
solutions need to be straightforward and easy-to-use by patients,
be straightforward to implement with low-cost widely available
technology, and utilize individualized predictive algorithms to
address the variability of the condition [23-25].
Evaluation of digital health interventions require multiple
perspectives to be considered within the evaluation [26]. We
have recently carried out a cohort study in which we have shown
that a tablet computer-based system for supporting patients with
COPD is acceptable to them and feasible to use [23,27].
We therefore set out to determine the efficacy of an
Internet-linked, tablet computer-based system of monitoring,
and self-management support (EDGE‚ sElf-management anD
support proGrammE) in improving quality of life and clinical
outcomes when used by patients with moderate to very severe
COPD.
Methods
Trial Design
EDGE for COPD is a multicenter, randomized controlled trial
of 12-month duration [28]. Patients were individually
randomized to receive either a system of care (the EDGE
intervention) delivered via a digital health, Internet-linked
platform implemented on a low-cost tablet computer (the EDGE
platform) providing monitoring and self-management support
or standardized usual care in a 2:1 allocation ratio (Figure 1).
A 2:1 allocation ratio was chosen to maximize the information
available about the use of the system across the population of
individuals with COPD [29]. There were no changes to the
design or methods of the study after recruitment commenced.
An embedded qualitative study was used to carry out a process
evaluation and to explore the experience of using the system.
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Figure 1. Participant flow legend. a: not mutually exclusive. b: defined as using the intervention for at least 30 days, during which time it was used for
at least 3 out of 7 days per week. MRC: Medical Research Council; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; COPD: chronic
obstructive pulmonary disease, SGRQ-C: St George’s Respiratory Questionnaire for COPD.
Participants
Eligibility Criteria for Participants
Eligible patients were aged ≥40 years with a confirmed diagnosis
of COPD defined as a forced expiratory volume in 1 s (FEV1),
post-bronchodilation of <70% [2], and a predicted ratio of FEV1
to forced vital capacity of <0.70. Eligible patients had a
smoking-pack history >10 pack-years and a Medical Research
Council dyspnea score of ≥2. Further trial eligibility criteria are
reported in the trial protocol [28].
Setting
Patients were recruited from a variety of settings encompassing
primary and secondary care as well as community services.
Patients attending respiratory hospital outpatient clinics and
pulmonary rehabilitation courses in the adjacent counties of
Oxfordshire and Berkshire, UK, were invited to participate. In
addition, eligible patients were identified from primary care
clinics and from those recently (within the preceding 2 weeks)
discharged from hospital following a COPD-related admission.
Trial Interventions
Intervention Development and Specification
On the basis of open-source app software, the EDGE platform
was designed to be integrated in clinical care, by a team of
clinicians and engineers working with patients. The platform
was refined in a 6-month cohort study of a group of patients
with COPD, who were selected using eligibility criteria
matching those of the trial [27].
The EDGE intervention was designed to include tools to help
patients identify exacerbations and to monitor their condition;
to help support good compliance with inhaled medication; and
to support psychological well-being. It incorporates a daily
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symptom diary consisting of standard questions about symptoms
based on previous trial protocols [30,31]. Questions include
general well-being, cough, breathlessness, sputum (quantity
produced and color), and use of medications. A 30-s period of
data acquisition using a Bluetooth-enabled pulse oximeter with
finger probe (Nonin, PureSAT, 9560BT) manufactured by Nonin
Medical Inc of Plymouth, Minnesota, USA, allows daily
collection of heart rate and oxygen saturation data. Mood
screening questionnaires [32-34] were presented each month
for completion; further details are given in Multimedia Appendix
1.
The EDGE platform also includes a number of software
modules, including videos tailored to the patient’s entries in the
symptom diary or answers to the mood-screening questionnaires.
These videos provide additional self-management support, and
are listed in Multimedia Appendix 1. These include inhaler
techniques, pulmonary rehabilitation exercises, and
self-management techniques for breathlessness. All of the
multimedia components were developed by the local clinical
respiratory team and are based on current pulmonary
rehabilitation interventions, for which there is good evidence
of effectiveness in improving quality of life for patients with
COPD [35]. As soon as the patient finishes using the app, data
is securely transmitted to a server hosted behind NHS firewalls.
Use of the EDGE Platform
Participants allocated to receive the EDGE platform-based
intervention were provided with an Android tablet computer
(Samsung Galaxy Tab) running the app software and a
Bluetooth-enabled oximeter probe.
Participants were briefly instructed on the use of the EDGE
platform by the research nurse and given a brief information
booklet detailing its use. Patients were informed that the EDGE
platform was not a replacement for their usual clinical care, and
that in the event of deterioration in their health they should
contact their general practitioner or community respiratory nurse
as usual. The intention of this approach was to establish the safe
use of new technology, whereas not intervening in a way that
might expose individuals to unintended harms [36].
In an initial 6-week period of use, EDGE users completed the
symptom diary and recorded their oxygen saturation and heart
rate with the pulse oximeter on a daily basis. Following this
initial run-in period, the distributions of values for the oxygen
saturation, heart rate, and symptom scores were calculated for
the run-in period for each participant. The 97th centile was
computed for the distribution of heart rate and symptom score,
and the 3rd centile for the distribution of oxygen saturation;
these were then used as the threshold for the participant safety
alert for that parameter. The option to modify thresholds
following a hospital admission was available. Participants
continued to input their symptom data and clinical recordings
daily throughout the duration of the trial.
One of three respiratory clinicians (nurse, physiotherapist, or
doctor) reviewed a summary of the oxygen saturation, heart
rate, and symptom diary module data twice weekly to ensure
that data transmission was taking place and to deal with safety
alerts. Data were assigned priority according to the number of
“alerts” in the most recent two weeks since the last review. In
this context, alerts were generated when the vital sign value
(pulse rate or oxygen saturation) went above (or below) the
safety threshold or the overall symptom score went above the
safety threshold.
If data were not received or there were safety alerts, the
participant record was accessed for review. If, on reviewing the
data, there was judged to be a clinically important change in the
data, then the patient was contacted either via message or
telephone. A clinically important parameter was defined as
either heart rate or symptom score moving above the 97th centile
or oxygen saturation falling below the 3rd centile, as defined
by baseline observation and persisting for at least 2 days. If
depression or anxiety scores equaled or exceeded a threshold
of 10, then the patient’s general practitioner was informed by
letter. The intervention is summarized in Multimedia Appendix
2.
The Standardized Usual Care Intervention
Participants allocated to receive standardized usual care were
provided with all the information given to those allocated to
use the EDGE system, but without the use of a tablet computer
or the facility for daily monitoring of symptoms and
physiological variables. Participants were provided with leaflets
based on those currently produced by the Oxfordshire
Community Respiratory service. Further details are given in
Multimedia Appendix 3.
Primary Outcome Measure
The primary outcome was the change in St George’s Respiratory
Questionnaire for COPD (SGRQ-C) [37], which was used to
assess COPD-specific health status from baseline to 1 year in
patients with moderate to very severe COPD.
Secondary Outcome Measures
The following secondary endpoints were used to evaluate the
impact of the intervention in comparison with usual care: (1)
impact on hospital admissions (number of admissions and days
in hospital) and deaths; (2) the number of recorded exacerbations
defined as episodes in which antibiotics or oral steroids were
prescribed or in which the patients were seen in the accident
and emergency department or admitted to hospital in the
presence of an acute change in respiratory symptoms defined
as the presence of at least two symptoms, one of which should
be major (major symptoms: change in sputum, more breathless,
chest tight; minor symptom: unwell, tired, temperature, a cold)
or a report of a patient taking more salbutamol, either blue
inhaler or by nebulizer, for at least 48 h (Multimedia Appendix
1); (3) time to first exacerbation; (4) beliefs about respiratory
medicine use measured with the Beliefs about Medicines
Questionnaire [38]; (5) self-reported medication use measured
with the Medication Adherence Report Schedule [38]; (6)
self-reported smoking cessation; (7) mood measured with the
Standard Checklist 20-item Questionnaire (SCL-20) for
depression [39] and the Standard Checklist 10-item Anxiety
Measure (SCL-10A) [40]; and (8) a comprehensive measure of
health status using the EuroQol 5-Dimension Questionnaire
(EQ-5D) [41]. The SCL20 and SCL-10A are derived from a
90-question standard measure and have been used extensively
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to measure mood and anxiety as outcome measures in studies
with people who have long-term conditions. The EQ-5D
includes 5 questions asking about mobility, self-care, usual
activities, pain and discomfort, and anxiety or depression. Each
question has a 3-level response, and the responses are used to
estimate a preference weight for that health status, presented as
a single index value.
Details of number and duration of hospital admissions were
measured by self-report and confirmed where possible by review
of hospital discharge letters and central hospital admissions
data. Records of deaths were obtained from general practices
and further details were obtained, where necessary, from hospital
records. Details of exacerbations of COPD were recorded on a
record form held by all participants [28].
Sample Size
The sample size calculations were based on the number of
patients required to demonstrate a mean difference of 6.6 on
the St George’s Respiratory Questionnaire between the two
allocated groups, at 12-months from randomization (equivalent
to 7.3 on SGRQ-C) [37]. We estimated the SD at 12.7 based on
a study using the SGRQ-C [42]. For a power of 90% and
significance level of .05 (2-sided), with 2:1 allocation between
intervention and usual care and allowing for 10% loss to
follow-up, we required 165 patients.
We also had 98% power to identify the difference in admissions
to hospital at 3 months based on effect sizes of previous
intensive interventions with this group of patients [7], and 52%
power to detect the difference in admissions at 12 months based
on a systematic review of interventions in COPD [43]. In both
cases, a 5% loss to follow-up was assumed.
Randomization
Participants were randomized with an allocation ratio of 2:1
intervention to usual care using Sortition V.1.2 [28]. The
research nurse carried out randomization by accessing Sortition
using a Web-browser on a tablet computer at the assessment
visit only after completion of consent procedures and baseline
measurements, including completion of the SGRQ-C.
Trial Procedures
Recruitment
Potentially eligible patients were sent an invitation to participate
in the trial. The invitation included a patient information booklet,
a reply slip, and prepaid envelope. Patients who were interested
in participating were asked to return their reply slips by post to
the research team. The research nurse then contacted the patient
by telephone to arrange an initial assessment visit. At this visit,
eligibility was confirmed, written informed consent was
obtained, and baseline data were collected for those consenting
to participate.
All participants were assessed at baseline by a health care
professional and had finished self-completed measures before
randomization and intervention allocation. The use of medication
by participants was recorded at the baseline and follow-up
assessment visits. Information collected included type, dose,
and frequency of COPD medication (tablets and inhalers) as
well as a list of other medication taken. A detailed smoking
history was taken at the baseline assessment visit; self-reported
smoking status was recorded at subsequent assessments. All
participants had either a written or tablet computer held action
plan (uploaded as Multimedia Appendix 3) for use with
changing symptoms, and were encouraged to ensure that, in
line with standard practice, they had reserve supplies of
antibiotics and steroids.
Patient Follow-Up and Retention
Patients remained in the trial for 12 months with assessments
at a baseline visit, 3, 6, and 12 months. The primary outcome
measure was collected at baseline, and 6 and 12 months after
randomization. Secondary outcome measures were collected at
baseline, 3, 6, and 12 months.
Postal reminders were sent before all follow-up assessment visit
dates. The 3-month assessment was a telephone contact with
patients. For patients allocated to standardized usual care, a
reminder was posted before the assessment date. The 6 and 12
months visits were carried out either at home or at clinic.
Self-completed outcome measures were completed without
guidance by the research team and before any further assessment
or discussion of clinical care. Research and clinical teams were
trained in the potential for measures to be biased by their
interactions with participants. A record of all contacts with trial
participants was kept to examine potential for interactions with
patients not specified in the trial protocol.
All patients had the right to withdraw from the trial at any point,
without providing a reason. Those patients who withdrew from
receiving the intervention were asked if they would be willing
to provide follow-up information within the trial at the 6- and
12-month assessment points. If patients declined, no further
information was collected.
Statistical Methods
The principal comparisons were performed on an
intention-to-treat basis. The trial results are presented as
comparative summary statistics (difference in response rates or
means) with 95% CI. A linear mixed-effects model was used
to analyze SGRQ-C including randomized group (intervention
or control), time point (6 months and 12 months), baseline
SGRQ-C score, age (analyzed continuously), gender, current
smoking status (yes or no), severity of COPD (according to
NICE clinical guidelines or GOLD classification, moderate or
severe or very severe), and site as fixed effects and a
patient-specific random intercept. Treatment-time interaction
was included in the model to assess the treatment effect at 12
months. Higher scores reflect better quality of life compared
with lower scores. Binary outcomes were analyzed using
log-binomial regression, adjusting for covariates as described
above. The threshold for statistical significance was less than
P=.05 with no adjustments made for multiple testing among
secondary outcomes.
The intervention effect was assessed by analysis of subgroups
defined by severity of COPD, smoking status, hospital admission
in the previous year, attending a pulmonary rehabilitation course
in the previous year, and the presence or absence of live-in
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support. A full detailed statistical analysis plan was prepared
before the final analysis by a trial statistician.
The EDGE COPD trial was carried out in conformance with
the principles of the current version of the Declaration of
Helsinki and the other regulations in force. The trial is registered
at ISRCTN 40367841.
Results
Trial Progress and Baseline Characteristics of
Participants
The CONSORT flow chart is presented in Figure 1. The reasons
for patient withdrawal are also detailed in Figure 1. The first
patient was randomized on June 26, 2013 and follow-up was
completed on July 27, 2015.
Baseline characteristics of trial participants are summarized in
Table 1 and in Multimedia Appendix 1. There were no relevant
differences in characteristics between those assigned to EDGE
and to usual care.
A total of 14 patients, who were allocated to receive the EDGE
system, withdrew from the trial of whom 5 died: 7 withdrew
from the usual care group with 4 deaths (Figure 1).
Use of the System
Out of the 110 patients who were part of the intervention arm
of the study, 100 patients were in the study for at least 180 days.
Compliance with use of the system was a mean (SD) of 5.9 (1.1)
days per week of use across all patients (range 1.4-7.0). Among
the 100 patients, only 2 patients had a compliance of less than
3 times per week. The video clips offered to intervention group
participants were used with varying frequency. The videos
relating to mood and breathing exercises were reviewed more
frequently than others (Multimedia Appendix 1). In total, 90%
(99/110) of participants viewed at least one video. The mean
(SD) number of videos viewed by participants was 5 (3.5) and
the mean number of times a video was viewed was 22.5 (19.9).
The mean (SD) number of accesses made by the nurse on the
website to the data for each participant in the intervention group
was 33.4 (SD 15.4, range 11-79), that is, an average of 2.78
accesses per patient per month.
Primary Outcome
Quality of life as measured with the SGRQ-C improved in
patients allocated to both the EDGE system and to usual care
from baseline to 6 months, and again to 12 months. The
estimated difference in SGRQ-C at 12 months (EDGE
system−usual care) was −1.7 with a 95% CI of −6.6 to 3.2
(P=.49). SGRQ-C scores and changes over time are summarized
in Table 2. Data were available on 84.5% (93/110) of patients
in the EDGE system group, and from 85.7% (48/56) patients
in the usual care group.
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Table 1. Baseline characteristics of participants.
Standard Care
n=56
EDGEa intervention
n=110
Characteristics
Clinical data
34 (60.7)68 (61.8)Male, n (%)
69.8 (10.6)69.8 (9.1)Age, mean (SDb)
29.1 (7.8)28.6 (7.1)BMIc, mean (SD)
50.1 (16.9)47.4 (15.6)FEV1d, mean (SD)
49.8 (11.5)47.6 (11.3)FEV1 or FVCe, mean (SD)
5 (4-6)5 (3-6)Number of COPDfmedications, median (IQRg)
5 (2.5-8)4 (2-7)Number of other medications, median (IQR)
Smoking history
13 (23.2)23 (20.9)Current, n (%)
8 (14.3)17 (15.5)Ex-smoker (<2 years), n (%)
35 (62.5)70 (63.6)Ex-smoker (≥2 years), n (%)
COPD severity
23 (41.1)41 (37.3)Moderate, n (%)
33 (58.9)69 (62.7)Severe or very severe, n (%)
MRCh dyspnoea score, N (%)
10 (17.9)17 (15.5)2
39 (69.6)74 (67.3)3
7 (12.5)19 (17.3)4
47 (83.9)89 (80.9)Comorbid conditions including high blood pressure, osteoporosis, high cholesterol, diabetes, heart disease,
and depression), N (%)
Patient reported outcome measures
55.5 (16.2)56.4 (19.7)SGRQ-C (St George’s Respiratory questionnaire for COPD patients), mean (SD)
0.3 (0-0.5)0.3 (0.1-0.9)SCL-10Ai, median (IQR)
0.68 (0.3-1.1)0.53 (0.3-1.15)SCL-20j, median (IQR)
25.3 (5.7)24.6 (4.8)BMQ (Beliefs about Medicines Questionnaire), mean (SD)
22.5 (3.8)23.4 (2.3)MARS (Medicines Adherence Report Scale), mean (SD)
0.63 (0.24)0.62 (0.24)EQ-5DkIndex, mean (SD)
22,777 (7261.5)22,440 (7951.9)Deprivation scorel, mean (SD)
aEDGE: sElf-management anD support proGrammE.
bSD: standard deviation.
cBMI: body mass index.
dFEV1: forced expiratory volume in 1 s.
eFVC: forced vital capacity.
fCOPD: chronic obstructive pulmonary disease.
gIQR: interquartile range (25th, 75th percentiles).
hMRC: Medical Research Council.
iSCL-10A: Standard Checklist 10-item Anxiety Measure.
jSCL-20: Standard Checklist 20-item Questionnaire.
kEQ-5D: EuroQol 5-Dimension Questionnaire.
lOn the basis of postcode with deprivation rankings accessed from the UK Office of National Statistics.
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Table 2. Primary outcome—St George’s Respiratory Questionnaire for chronic obstructive pulmonary disease.
Standard care
N=56
EDGEaintervention
N=110
Primary Outcome
SGRQ-Cb
55.5 (16.2)56.4 (19.7)Baseline, mean (SDc)
54.3 (21.8)
N=51
55.7 (20.2)
N=98
6 months, mean (SD)
56.8 (20.9)
N=48
56.9 (19.5)
N=93
12 months, mean (SD)
Difference between groupsd
0.99 (−3.81 to 5.78; .69)6 months, mean (95% CI; P value)
−1.74 (−6.65 to 3.16; .49)12 months, mean (95% CI; P value)
aEDGE: sElf-management anD support proGrammE.
bSGRQ-C: St George’s Respiratory Questionnaire for COPD.
cSD: standard deviation.
dFrom mixed effects model including randomized group (intervention or control), time point (6 months and 12 months), baseline SGRQ-C score, age
(analyzed continuously), gender, current smoking status (yes or no), severity of COPD (according to NICE clinical guidelines or GOLD classification,
moderate or severe or very severe), and site as fixed effects and a patient-specific random intercept. Higher scores reflect better quality of life compared
with lower scores.
Secondary Outcomes
Secondary outcomes are summarized in Table 3. Deaths did not
differ between groups. Numbers of exacerbations did not differ
overall between groups. The relative risk of hospital admission
for EDGE was 0.83 (0.56-1.24, P=.37) compared with usual
care. There was a significant difference in overall health status
measured with the 5-Level EuroQol 5-Dimension Questionnaire
(EQ-5D-5L) between groups 0.076 (0.009-0.14, P=.03), with
better health status for the digital health group. There were fewer
visits to the GP practice nurses 1.5 (digital health) versus 2.5
(usual care), P=.03 in comparison to the usual care group. The
difference did not reach statistical difference for the median
number of visits to general practitioners: 4.0 (digital health)
versus 5.5 (usual care), P=.06. There was no difference in
Beliefs about Medicines Questionnaire (BMQ) or self-reported
medicines adherence (MARS, Medication Adherence Report
Scale), and no differences in self-reported smoking cessation.
Depression measured with the SCL-20 decreased in the EDGE
group and increased in the standard care, but the difference in
change between groups was not statistically significant. Anxiety
measured with the SCL-10A was unchanged in the EDGE group,
whereas increased in the usual care group, but again the
difference in change between groups was not statistically
significant.
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Table 3. Secondary outcomes baseline to 12 months.
Overall effect comparing EDGEaand usual careSecondary outcomes
P valueAdjusted treatment effectb(95% CI)Standard careEDGE intervention
.731.7c(−11.0 to 4.9)4 (7.1)6 (5.5)Death rates, n (%)
.370.83d(0.56-1.24)23 (41.1)38 (34.6)Number with at least one admission, n (%)
.391.21f(0.79-1.84)1 (0-3)1 (0-2)Number of exacerbations, median (IQRe)
.44−0.64i(−2.28 to 1.00)−0.80 (4.69)−1.26 (5.33)Change in BMQg, mean (SDh)
.770.10j(−0.57 to 0.77)0.33 (3.65)0.17 (2.47)Medication Adherence Report Schedule, mean (SD)
.711.40k(0.24-7.96)41 (85.4)76 (81.7)Smoking cessation, n (%)
.030.076i(0.009-0.14)−0.08 (0.19)0.01 (0.21)Change in EQ-5D-5Ll, mean (SD)
.10−0.13i(−0.29 to 0.03)0.14 (0.56)−0.04 (0.46)Change in SCL-20m, mean (SD)
.980.002i(−0.19 to 0.19)0.13 (0.43)0.03 (0.59)Change in SCL-10An, mean (SD)
.910.32i(−5.58 to 6.22)−1.40 (5.67)−0.78 (10.23)Change in lung function, mean (SD)
.06-5.5 (2-10)4 (2-7)Number of GPocontacts (surgery), median (IQR)
.03-2.5 (1-7)1.5 (1-3)Number of nurse contacts (surgery), median (IQR)
aEDGE: sElf-management anD support proGrammE.
bAdjusted for baseline values and minimization factors.
cDifference in proportion.
dRelative risk.
eIQR: interquartile range.
fIncidence rate ratio.
gBMQ: Beliefs about Medicines Questionnaire.
hSD: standard deviation.
iDifference in change in mean.
jDifference in mean.
kOdds ratio.
lEQ-5D-5L: 5-Level EuroQol 5-Dimension Questionnaire.
mSCL-20: Standard Checklist 20-item Questionnaire.
nSCL-10A: Standard Checklist 10-item Anxiety Measure.
oGP: general practitioner.
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Figure 2. Subgroup analyses for primary outcome.
Subgroup Analysis of Primary Outcome
Prespecified subgroup analyses for the change in SGRQ-C
between intervention groups are summarized in Figure 2.
Severity of COPD, current smoker, and no previous hospital
admissions in the last year appeared to favor the EDGE system,
although interaction terms did not reach statistical significance.
Safety Data
There was no difference in the rates of adverse events or serious
adverse events between groups, and none of these events was
deemed to be trial or intervention-related. Primary care clinicians
were contacted on the same day that a clinically important safety
alert was identified.
Costs
The cost of each tablet computer used was £319 and the cost of
the pulse oximeter probe was £399. Reviewing patient data on
the clinician website using the prioritization algorithms took a
median (IQR, interquartile range) of 1.2 h per session (2.9),
with a median number of participants accessed for each session
of 16 (54). The cost of a hospital admission was estimated as
£2900, a GP appointment as £36, and a practice nurse
appointment as £11 [44]. The respiratory clinicians reviewing
the data reported that up to one phone call a week to a general
practitioner, practice or respiratory nurse was required, following
patient data review.
Discussion
Principal Findings
This trial provides evidence that use of a tablet computer-based
system of monitoring and self-management support does not
impact, either positively or negatively on COPD-specific health
status over a period of 12 months. However, the finding of a
significant improvement in prespecified secondary outcomes
supports a beneficial impact on broader measures of health
status and number of visits to practice nurses. Although the trial
did not test the intervention in a sufficiently large sample to
detect a significant difference between patients allocated to
intervention and usual care, the effect sizes observed for an
improved depression score, reductions in hospital admissions,
and reduction in visits to a general practitioner compared with
usual care suggest a need for further evaluation.
This trial was carried out in a representative population of
individuals with moderate to very severe COPD using minimal
exclusion criteria. It employed state-of-the art trial management
including use of minimization to balance groups, an unbalanced
allocation to allow the possibility of examining the effect of the
EDGE platform across a wide range of participants, and
measures to avoid contamination. In contrast to several recently
reported trials of telehealth in COPD, the equipment was
affordable and did not require specialist installation. Features
of the EDGE platform addressing previous concerns about
telehealth systems include the use of a generic tablet computer,
access through icons rather than a keyboard, use of Bluetooth
sensors with error-checking algorithms to ensure high-quality
data, support for patient interpretation of data, and tailored
self-management content [45]. The study protocol mandated
patient contact when patient-specific, rather than study-wide
thresholds were reached. The prioritization algorithms used to
implement personalized alerting ensured that the workload of
the nurses reviewing the patient data was kept to manageable
levels (a median of 1.2 h per session, with a median of 16
patients accessed per session; 2 sessions per week). This trial
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addresses previous concerns about the lack of well-designed
randomized controlled trials with appropriate follow-up raised
in a recent review of telemedicine interventions for COPD [46].
The use of a self-reported primary outcome measure is a
potential limitation, but this was completed before measurement
and other data collection at the final visit. Other limitations of
the trial design that could be addressed in future work include
moving to the use of the updated GOLD classification to
characterize participants at baseline. Although no adjustment
for testing of multiple secondary outcomes was made, all were
prespecified.
As with other trials [22,47,48], and in line with a systematic
review of telehealth trials [49], an impact on COPD-specific
health status was not observed. Although COPD-specific health
status is an important aspect of COPD that has been shown to
be responsive to group and one-to-one interventions [50], a
digital health intervention used on its own may not replace a
more intensive and personalized intervention for many patients.
However, other outcomes are also important, including broader
measures of health status, psychological health measures, and
use of hospital services. It is possible that use of the intervention
in clinical practice may lead to changes in the behavior of
doctors and nurses, and the way that the health system responds
to patients. These changes could further improve outcomes.
Further studies to evaluate the system may therefore need to be
carried out with clustering of intervention delivery by functional
units, for example, individual primary care sites.
The EDGE system was used daily, to send pulse oximeter and
diary data, by over 80% of the trial patients. The use of
algorithms on the tablet computer to assess quality of monitoring
data minimized false alerts from the system. The limited impact
observed on some secondary outcomes in this trial could be
mediated by regular self-monitoring and review of charted data
together with use of the educational and motivational material
available on the tablet computer, and, perhaps for some, the
wider use of the tablet computer to communicate with family
and friends. The effects observed in this trial could be further
enhanced by use of better predictive algorithms guiding self-
and clinician-management. Monitoring additional parameters
(eg, mobility) and prompting additional measurement may also
improve algorithm performance. The comprehensive data from
this trial, where the external monitoring of data was restricted
to ensuring patients’ safety, provide a source for predictive
modeling [24]. Predictive modeling from these data, along with
additional parameters (including mobility) will be integrated
into strategies for early treatment of exacerbations [51].
Strategies will include prompting for additional measurement
to improve the accuracy of predictions, graded alerts to patients
prompting clinical review or starting treatment, and alerts to
clinicians to proactively contact patients.
The trial intervention uses a novel implementation of telehealth
using a nonproprietary tablet computer designed for integration
into day-to-day life and clinical care. In addition to being
nonobtrusive, it provides, at relatively low cost in relation to
previous telehealth systems, facilities for monitoring,
communication, self-management support, and education
delivery. The development of the system was carried out
iteratively using best practice to involve patients, engineers, and
clinicians in repeated testing and assessment [52]. Future
iterations of the technology could extend beyond the limited
implementation of the EDGE system used in this study [36],
for example, in integration with electronic health records.
The underlying approach to implementing digital health within
this trial was to provide a system focused around the needs of
the patient, with collection of data that can be analyzed over a
period of time and used to inform future management. Data
from this trial will be used to evaluate the potential of
patient-specific tailored alerts, as well as informing the design
of multicenter trials to explore cost-effectiveness and potential
for reduction in hospital admissions [46]. The dataset would
also be available to test algorithms derived from other projects.
Conclusions
Although this clinical trial does not provide evidence for an
effect on COPD-specific health status from the EDGE digital
health system in comparison with usual care, there may be an
overall benefit to patients through better overall health status.
If an intervention with the effect sizes for reduced hospital
admissions and primary care visits of the magnitude reported
in this trial were implemented at scale, it would make an
important contribution to monitoring and self-management
support for people with moderate to very severe COPD.
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